



# SANJIVANI PARANTERAL LIMITED

205, P. N. Kothari Industrial Estate, L.B.S. Marg, Bhandup (W), Mumbai - 400 078, Maharashtra

Date: 16<sup>th</sup> February, 2026.

To,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 531569

Sub: Revised Press Release on Audited Financial Results (Standalone and Consolidated) for Third Quarter and Nine months ended on ended December 31<sup>st</sup>, 2025.

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find enclosed the press release on Audited Financial Results (Standalone and Consolidated) for the Third Quarter and Nine months ended on ended December 31<sup>st</sup>, 2025.

Kindly take the above information on your records.

Thanking You,  
Yours Faithfully,

**For Sanjivani Paranteral Limited**

**Ravikumar Bogam**  
Company Secretary Cum Compliance Officer

## Press Release

### Sanjivani Paranteral Limited reported a strong performance for the quarter ended 31<sup>st</sup> December 2025

**Mumbai, 13<sup>th</sup> February 13, 2026:** Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai having two manufacturing plants located at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. The company cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

**Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said,** we are pleased to report a strong performance in Q3FY26, driven by healthy growth in our base business. This quarter marks an important milestone for the Company as SPL Infusion Pvt. Ltd., Pune has contributed to consolidated revenues for the first time. The integration of the Pune facility has strengthened our manufacturing footprint and meaningfully supported the overall topline growth at the consolidated level. Our core business continues to demonstrate resilience and positive momentum across key markets. The Pune facility will gradually scale up its performance as capacity utilization improves over time. Looking ahead, the Company's expanded manufacturing capabilities, widening geographic reach, and strengthening product pipeline, supported by strategic investments made earlier, are expected to drive steady growth".

#### Financial Summary:

#### Q3 FY26 (Standalone):

- Revenue from operations grew by 20.25% YoY to Rs. 208.63 mn.
- EBITDA margin stood at 18.62%.
- Profit After Tax (PAT) stood at Rs. 26.16 mn (Grew 37.8% YoY).

Particulars (Rs. in mn.)	Q3FY26	Q3FY25	Q2FY26	9M FY26	9M FY25
Total Income	<b>211.5</b>	<b>176.6</b>	156.6	<b>547.4</b>	<b>527.0</b>
Gross Profit	<b>69.6</b>	<b>77.3</b>	53.3	<b>191.0</b>	<b>216.1</b>
Gross Margin (%)	<b>33.4%</b>	<b>44.6%</b>	34.4%	<b>35.2%</b>	<b>41.6%</b>
EBITDA incl. other income	<b>38.8</b>	<b>28.6</b>	24.1	<b>89.7</b>	<b>85.3</b>
EBITDA Margin (%)	<b>18.62</b>	<b>16.5%</b>	15.5%	<b>16.5%</b>	<b>16.4%</b>
PBT	34.9	25.1	21.9	79.8	77.0
PBT Margin %	16.7%	14.2%	14.0%	14.5%	14.6%
PAT	<b>26.1</b>	<b>19.0</b>	16.4	<b>59.8</b>	<b>59.1</b>
PAT Margin (%)	<b>12.37%</b>	<b>10.7%</b>	10.5%	<b>10.9%</b>	<b>11.2%</b>
Basic EPS (in INR)	2.13	1.62	1.33	4.87	5.06

**Segment-wise Performance:**

- **Injectables:** Revenue de-grew by 9.7% YoY to Rs. 116.7 mn.
- **Oral:** Revenue grew by 153.5% YoY to Rs. 86.4 mn.
- **Nutraceuticals:** Revenue stood at Rs. 5.6 mn in Q3FY26.

**Market-Wise Performance:**

- Exports (incl. Exports incentives) constitutes 76.9% of total revenue, while domestic constitutes the rest.
- Core markets of CIS (incl Russia), the Middle East & Africa and Latin America, accounted for 76.9% to Rs. 160.4 mn.

**9M FY26 (Standalone):**

- Revenue from operations grew 4.5% YoY to Rs. 542.5 mn.
- EBITDA margin stood at 16.5%
- Profit After Tax (PAT) stood at Rs. 59.8 mn. (Grew 1.3% YoY).

**Segment-wise Performance:**

- **Injectables:** Revenue grew by 6.57% YoY to Rs. 299.4 mn.
- **Oral:** Revenue grew by 6.61% YoY to Rs. 224.5 mn.
- **Nutraceuticals:** Revenue stood at Rs. 18.5 mn in Q3FY26.

**Market-Wise Performance:**

- Exports (incl. Exports incentives) constitutes 77.2% of total revenue, while domestic constitutes the rest.
- Core markets of CIS (incl Russia), the Middle East & Africa and Latin America, accounted for 77.2% to Rs. 418.7 mn.

**Q3 FY26 (Consolidated):**

- Revenue from operations grew by 27.17% YoY to Rs. 220.6 mn.
- EBITDA margin stood at 18.74%.
- Profit After Tax (PAT) stood at Rs. 27.76 mn (Grew 46.2% YoY).

**9M FY26 (Consolidated):**

- Revenue from operations grew 6.81% YoY to Rs. 554.5 mn.
- EBITDA margin stood at 16.64%
- Profit After Tax (PAT) stood at Rs. 61.45 mn. (Grew 4.01% YoY).

**Pritesh Jain**

Sanjivani Paranteral

Chief Financial Officer

[pritesh.jain@sanjivani.co.in](mailto:pritesh.jain@sanjivani.co.in)**DISCLAIMER:**

*Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*